Selected research
Industry Research
Women’s Health Drugs Industry Research Report 2026
Market perspective
The global Women’s Health Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Women’s Health Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Women’s Health Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Women’s Health Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Women’s Health Drugs include Johnson & Johnson, Novartis AG, Merck & Co, Mylan N.V., Pfizer Inc, Bayer AG, Amgen, Lupin (India) and Ferring Pharmaceuticals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Women’s Health Drugs market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Women’s Health Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Women’s Health Drugs Market by Company
Johnson & Johnson
Novartis AG
Merck & Co
Mylan N.V.
Pfizer Inc
Bayer AG
Amgen
Lupin (India)
Ferring Pharmaceuticals
Eli Lilly And Company
Allergan
Agile Therapeutics Inc
Women’s Health Drugs Segment by Type
Minastrin 24 Fe
XGEVA
Prolia
Mirena
EVISTA
Zometa
Reclast/Aclasta
Others (Premarin, ACTONEL, ORTHO TRI-CY LO)
Women’s Health Drugs Segment by Application
Contraceptives
Polycystic Ovary Syndrome
Hormonal Infertility
Menopause
Postmenopausal Osteoporosis
Endometriosis
Other Applications
Women’s Health Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Women’s Health Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Women’s Health Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Women’s Health Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Women’s Health Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Minastrin 24 Fe
- XGEVA
- Prolia
- Mirena
- EVISTA
- Zometa
- Reclast/Aclasta
- Others (Premarin, ACTONEL, ORTHO TRI-CY LO)
Applications
- Contraceptives
- Polycystic Ovary Syndrome
- Hormonal Infertility
- Menopause
- Postmenopausal Osteoporosis
- Endometriosis
- Other Applications
Companies covered
- Johnson & Johnson
- Novartis AG
- Merck & Co
- Mylan N.V.
- Pfizer Inc
- Bayer AG
- Amgen
- Lupin (India)
- Ferring Pharmaceuticals
- Eli Lilly And Company
- Allergan
- Agile Therapeutics Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Women’s Health Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Minastrin 24 Fe
- 2.2.3 XGEVA
- 2.2.4 Prolia
- 2.2.5 Mirena
- 2.2.6 EVISTA
- 2.2.7 Zometa
- 2.2.8 Reclast/Aclasta
- 2.2.9 Others (Premarin, ACTONEL, ORTHO TRI-CY LO)
- 2.3 Women’s Health Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Contraceptives
- 2.3.3 Polycystic Ovary Syndrome
- 2.3.4 Hormonal Infertility
- 2.3.5 Menopause
- 2.3.6 Postmenopausal Osteoporosis
- 2.3.7 Endometriosis
- 2.3.8 Other Applications
- 2.4 Assumptions and Limitations
3 Women’s Health Drugs Breakdown Data by Type
- 3.1 Global Women’s Health Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Women’s Health Drugs Forecasted Market Size by Type (2027-2032)
4 Women’s Health Drugs Breakdown Data by Application
- 4.1 Global Women’s Health Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Women’s Health Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Women’s Health Drugs Market Perspective (2021-2032)
- 5.2 Global Women’s Health Drugs Growth Trends by Region
- 5.2.1 Global Women’s Health Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Women’s Health Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Women’s Health Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Women’s Health Drugs Market Dynamics
- 5.3.1 Women’s Health Drugs Industry Trends
- 5.3.2 Women’s Health Drugs Market Drivers
- 5.3.3 Women’s Health Drugs Market Challenges
- 5.3.4 Women’s Health Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Women’s Health Drugs Players by Revenue
- 6.1.1 Global Top Women’s Health Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Women’s Health Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Women’s Health Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Women’s Health Drugs Head Office and Area Served
- 6.4 Global Women’s Health Drugs Players, Product Type & Application
- 6.5 Global Women’s Health Drugs Manufacturers Established Date
- 6.6 Global Women’s Health Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Women’s Health Drugs Market Size (2021-2032)
- 7.2 North America Women’s Health Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Women’s Health Drugs Market Size by Country (2021-2026)
- 7.4 North America Women’s Health Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Women’s Health Drugs Market Size (2021-2032)
- 8.2 Europe Women’s Health Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Women’s Health Drugs Market Size by Country (2021-2026)
- 8.4 Europe Women’s Health Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Women’s Health Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Women’s Health Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Women’s Health Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Women’s Health Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Women’s Health Drugs Market Size (2021-2032)
- 10.2 South America Women’s Health Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Women’s Health Drugs Market Size by Country (2021-2026)
- 10.4 South America Women’s Health Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Women’s Health Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Women’s Health Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Women’s Health Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Women’s Health Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Johnson & Johnson
- 12.1.1 Johnson & Johnson Company Information
- 12.1.2 Johnson & Johnson Business Overview
- 12.1.3 Johnson & Johnson Revenue in Women’s Health Drugs Business (2021-2026)
- 12.1.4 Johnson & Johnson Women’s Health Drugs Product Portfolio
- 12.1.5 Johnson & Johnson Recent Developments
- 12.2 Novartis AG
- 12.2.1 Novartis AG Company Information
- 12.2.2 Novartis AG Business Overview
- 12.2.3 Novartis AG Revenue in Women’s Health Drugs Business (2021-2026)
- 12.2.4 Novartis AG Women’s Health Drugs Product Portfolio
- 12.2.5 Novartis AG Recent Developments
- 12.3 Merck & Co
- 12.3.1 Merck & Co Company Information
- 12.3.2 Merck & Co Business Overview
- 12.3.3 Merck & Co Revenue in Women’s Health Drugs Business (2021-2026)
- 12.3.4 Merck & Co Women’s Health Drugs Product Portfolio
- 12.3.5 Merck & Co Recent Developments
- 12.4 Mylan N.V.
- 12.4.1 Mylan N.V. Company Information
- 12.4.2 Mylan N.V. Business Overview
- 12.4.3 Mylan N.V. Revenue in Women’s Health Drugs Business (2021-2026)
- 12.4.4 Mylan N.V. Women’s Health Drugs Product Portfolio
- 12.4.5 Mylan N.V. Recent Developments
- 12.5 Pfizer Inc
- 12.5.1 Pfizer Inc Company Information
- 12.5.2 Pfizer Inc Business Overview
- 12.5.3 Pfizer Inc Revenue in Women’s Health Drugs Business (2021-2026)
- 12.5.4 Pfizer Inc Women’s Health Drugs Product Portfolio
- 12.5.5 Pfizer Inc Recent Developments
- 12.6 Bayer AG
- 12.6.1 Bayer AG Company Information
- 12.6.2 Bayer AG Business Overview
- 12.6.3 Bayer AG Revenue in Women’s Health Drugs Business (2021-2026)
- 12.6.4 Bayer AG Women’s Health Drugs Product Portfolio
- 12.6.5 Bayer AG Recent Developments
- 12.7 Amgen
- 12.7.1 Amgen Company Information
- 12.7.2 Amgen Business Overview
- 12.7.3 Amgen Revenue in Women’s Health Drugs Business (2021-2026)
- 12.7.4 Amgen Women’s Health Drugs Product Portfolio
- 12.7.5 Amgen Recent Developments
- 12.8 Lupin (India)
- 12.8.1 Lupin (India) Company Information
- 12.8.2 Lupin (India) Business Overview
- 12.8.3 Lupin (India) Revenue in Women’s Health Drugs Business (2021-2026)
- 12.8.4 Lupin (India) Women’s Health Drugs Product Portfolio
- 12.8.5 Lupin (India) Recent Developments
- 12.9 Ferring Pharmaceuticals
- 12.9.1 Ferring Pharmaceuticals Company Information
- 12.9.2 Ferring Pharmaceuticals Business Overview
- 12.9.3 Ferring Pharmaceuticals Revenue in Women’s Health Drugs Business (2021-2026)
- 12.9.4 Ferring Pharmaceuticals Women’s Health Drugs Product Portfolio
- 12.9.5 Ferring Pharmaceuticals Recent Developments
- 12.10 Eli Lilly And Company
- 12.10.1 Eli Lilly And Company Company Information
- 12.10.2 Eli Lilly And Company Business Overview
- 12.10.3 Eli Lilly And Company Revenue in Women’s Health Drugs Business (2021-2026)
- 12.10.4 Eli Lilly And Company Women’s Health Drugs Product Portfolio
- 12.10.5 Eli Lilly And Company Recent Developments
- 12.11 Allergan
- 12.11.1 Allergan Company Information
- 12.11.2 Allergan Business Overview
- 12.11.3 Allergan Revenue in Women’s Health Drugs Business (2021-2026)
- 12.11.4 Allergan Women’s Health Drugs Product Portfolio
- 12.11.5 Allergan Recent Developments
- 12.12 Agile Therapeutics Inc
- 12.12.1 Agile Therapeutics Inc Company Information
- 12.12.2 Agile Therapeutics Inc Business Overview
- 12.12.3 Agile Therapeutics Inc Revenue in Women’s Health Drugs Business (2021-2026)
- 12.12.4 Agile Therapeutics Inc Women’s Health Drugs Product Portfolio
- 12.12.5 Agile Therapeutics Inc Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst